DocGo Inc. (DCGO) Earnings Call Transcript & Summary

May 8, 2024

NASDAQ US Health Care Health Care Providers and Services earnings 55 min

Earnings Call Speaker Segments

Mike Cole

executive
#1

Thanks, Operator. Before I hand things over to management, I'd like to offer a few comments about forward-looking statements. Everything shared on this conference call that isn't a statement of historical fact counts as a forward-looking statement. Such forward-looking statements may be identified by terms like may, will, plan, potential, could, goal, outlook, design, anticipate, aim, believe, estimate, expect, intend, guidance, confidence, target, project, and similar expressions. These forward-looking statements don't guarantee future performance, and we can't assure you that our plans, intentions, outcomes, results, or expectations will be achieved or realized. Forward-looking statements are inherently exposed to substantial risks, uncertainties, and assumptions, many beyond our control, which could cause our actual results or outcomes, or when results or outcomes occur, to differ materially from those contained in our forward-looking statements; these risks, uncertainties, and assumptions include, but aren't limited to, those covered in our risk factors and elsewhere in DocGo's annual report on Form 10-K, quarterly reports on Form 10-Q, and other reports and statements DocGo has filed with the SEC, to which your attention is directed. Actual outcomes and results, or when results or outcomes occur, may differ materially from what these forward-looking statements express or imply. Additionally, today's call references non-GAAP financial measures. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are provided directly as part of this call or included in our earnings release, which is posted on our website, docgo.com, as well as filed with the Securities and Exchange Commission. The information contained in this call is accurate as of only the date discussed. Investors shouldn't assume that statements will remain relevant and operative at a later time. We undertake no obligation to update any information discussed in this call to reflect events or circumstances after the date of this call or to reflect new information or the occurrence of unanticipated events, except as to the extent required by law. At this time, it is now my pleasure to turn the call over to Mr. Lee Bienstock, CEO of DocGo. Lee, please go ahead.

Lee Bienstock

executive
#2

Thank you, Mike, and thanks to everyone for being here today. I couldn't be happier with how we performed in Q1 and how we executed operationally across every area. We're achieving significant momentum in growing our care gap closure initiatives alongside large insurance partners. We take pride in the wide-ranging population health services we deliver to underserved communities, and our medical transportation operations with hospital systems continue to be robust and are expanding at a healthy pace. Revenue came in at $192.1 million, and we posted record adjusted EBITDA of $24.1 million. During Q1, we served a record count of medical transportation patients, rolled out our primary care offering, debuted a new mobile X-ray program, and kept recruiting top talent for our leadership team. To begin, I'd like to go over our revised guidance for 2024. During our previous earnings call, we gave guidance for 2024 anticipating annual revenues between $720 million and $750 million, along with Adjusted EBITDA of $80 million to $85 million. Because the winddown of migrant-related projects and the revenues tied to them has come faster than expected, we're revising our revenue and Adjusted EBITDA guidance; we now expect full-year 2024 revenues of $600 million-$650 million. That figure consists of roughly $320 million-$350 million in migrant-related revenues plus $280 million-$300 million from our base business lines going forward, our medical transportation business, and our non-migrant mobile health business. This guidance cut stems entirely from the quicker winddown of certain migrant services projects. The base business delivered as expected in Q1 and ought to stay on track with original guidance for the remainder of the year. If we break that base revenue down further, we anticipate non-migrant mobile health revenues of about $105 million and transportation revenues of $195 million at the top end of the range. We now expect adjusted EBITDA for the full year to land in a range of $65 million-$75 million, which works out to an 11% adjusted EBITDA margin; we've started a program aimed at optimizing our operating expenses so we can hold adjusted EBITDA margins steady as migrant-related revenues wind down. I'd also like to offer some perspective beyond 2024. As we look toward 2025, our plan is to grow base revenue from $280 million to $300 million up to $400 million, with $50 million in adjusted EBITDA expected; we anticipate that $400 million in revenue breaking down as follows: about $175 million in non-migrant mobile health and $225 million in transportation. Looking at it by customer vertical, we expect $250 million from hospital system customers, $100 million from municipal customers, and $50 million from payer and provider programs. Although it's possible a few of the current migrant-related projects might extend into 2025, whatever migrant revenues arise in 2025 would come on top of this base amount. Our 2025 base revenue target would amount to growth of over 30% compared with 2024. As always, I'd like to share a few drivers from our three customer verticals that are helping fuel this growth. To start, our collaboration with insurers keeps picking up speed, and we have now secured contracts centered on closing care gaps with 2 of the country's 5 biggest health insurance providers. We're busy mapping out growth with payers in California and New York, and additional ones are in the pipeline; our creative approach involves getting health plan members to tackle care gaps through easy at-home visits while delivering continuous care for people who don't have a traditional primary care provider. In fact, we're thrilled to share that during the quarter just ended, DocGo introduced its mobile and virtual PCP service to serve the patients we encounter daily even better, and we're striving to extend this new service to additional patients via our health plan partnerships. We think that by acting as the patient's PCP through our distinctive in-home and virtual approach, we can assist in coordinating their care more effectively and enhance health outcomes. We're enthusiastic about the potential of our novel primary care strategy for our patients. Take, for instance, one of our earliest PCP patients, who left a rehab center in December and required cataract surgery, yet she was recuperating from a stroke at home and had no relationship with a PCP able to give a clearance exam for her operation. We rolled out our blended virtual and in-home PCP service to give her a comprehensive exam, covering labs and an EKG. Once all the required testing was finished, we returned to her home and cleared her for her delayed eye surgery. This was an operation she urgently needed to enhance her quality of life, and it couldn't have happened without our visits. We currently have 8 distinct payer contracts established, which lets us use our mobile strengths to deliver broader health care access for populations that are traditionally difficult to reach and creates a foundation for future revenue growth; we also keep advancing with our remote monitoring and virtual care management services. We've inked fresh patient monitoring agreements with 2 sizable cardiology practices in Ohio and Delaware and rolled out 2 new virtual care programs in New Jersey and Pennsylvania. To illustrate how we grow this business, consider that last year, a health plan with 3 million members signed with DocGo to serve members throughout various states and lines of business, such as their Medicare, Medicaid, and commercial exchange health plans. They gave DocGo roughly 25,000 members who had identified care gaps, like no recent Hemoglobin A1c or blood pressure tests, past-due diabetic eye exams, kidney health evaluations, and bone density screenings. In under 5 months, we visited more than 1,400 members through in-home and virtual appointments and assisted in boosting quality metrics by closing over 3,500 HEDIS Stars-related care gaps. Given these outcomes, the health plan is increasing the number of patients it assigns to DocGo by 50% in 2024. For 2025, our aim in expanding the insurance and patient monitoring side of the business is to finish more than 65,000 care gap closures, bring 10,000 PCP patients on board, and keep tabs on over 70,000 patients. All of those figures align with the partnerships we have now as well as the pipeline of partners to come. Next, our transportation service vertical posted record trip volumes in Q1, driven partly by our big health system partners in the U.S. and the U.K. seeing higher patient volumes. We take pride in supporting capacity management efforts through close collaboration with our hospital partners. At the same time, we have completely rolled out our leased-hour program with Main Line Health in Pennsylvania; we were awarded a leased-hour 911 contract in Dover, Delaware, and have kicked off medical transportation at Lenox Hill Hospital in Manhattan; we keep growing our event medical services, which includes a new contract with Ballpark Commons in Wisconsin along with our work with New York City Football Club. On top of that, we are steadily widening our mobile health footprint among this customer base. Mobile health services remain a comparatively small piece of the equation right now, yet they could expand significantly over time, since we can help our customers keep lower acuity patients from ending up in the emergency room, and that is precisely what our health system customers are after; and third, in our municipal population health business, we unveiled an exciting new mobile X-ray program, which we expect will first be used to help diagnose tuberculosis among underserved populations, though we think it holds far broader usefulness beyond that. We showcased our first Mobile X-ray unit at the National Tuberculosis Coalition of America's annual TB conference in Baltimore, Maryland, and we believe this program carries considerable near-term growth potential, because many geographies around the country are seeing a sharp rise in TB cases; we are already witnessing strong municipal interest in this offering and look forward to providing further updates as the program grows. Looking ahead, our growth will come from our pipeline of municipal RFPs for larger, more sustainable behavioral health and population health programs. The noise around our migrant-related work ended up obscuring the core story of DocGo. My role is to remind everyone what that story is; we have built our proprietary technology platform so we can efficiently and profitably deploy thousands of clinicians and hundreds of mobile units every day to bring care to patients wherever they happen to be. In a post-pandemic world that is waking up to the fact that telehealth by itself is not enough to genuinely change patient outcomes, our mix of technology and caring hands-on clinical services lets us accomplish what telehealth by itself cannot. We can meet patients on their terms, in person, broadening access, and helping keep people out of the hospital, which ultimately is what everyone wants. We have created a differentiated model, a differentiated product, and a differentiated patient experience. A vast marketplace exists, an entire ecosystem of collaborators, and countless individuals relying on our help; having said that, I'll now pass things along to Norm, who will walk through the financial details.

Norman Rosenberg

executive
#3

Thanks, Lee, and good afternoon everyone. For Q1 2024, total revenue came in at $192.1 million, which represents a 70% jump compared to the same period in 2023. Mobile Health revenue during Q1 2024 reached $143.9 million, almost twice what we saw in Q1 2023; growth occurred across a number of projects, business lines, and geographies. That said, most of the year-over-year increase in revenue came from migrant-related projects we ran in New York for both HPD and H&H. Transportation Services revenue rose to $48.2 million in Q1 2024, which is 20% above the Transportation Services revenues recorded during Q1 2023. Almost every transportation market saw revenue growth year over year, extending the momentum that started in the second half of 2022. In Q1, Mobile Health revenues made up roughly 75% of total revenues while Transportation Services contributed 25%. Net income for Q1 2024 stood at $10.6 million, versus a net loss of $3.9 million in Q1 2023, driven by higher revenues and wider gross margins. Our effective tax rate in Q1 was about 33%, and we think that's a solid assumption going forward. Adjusted EBITDA for Q1 2024 was $24.1 million — the highest quarterly adjusted EBITDA figure we have ever posted and over four times the $5.6 million from last year's first quarter. The adjusted EBITDA margin reached 12.6% in Q1, compared to 5% in Q1 2023. Total gross margin percentage for Q1 2024 was 35%, a significant increase from 28.1% in Q1 2023. Gross margin in Q1 2024 marked a continued rebound from the weak levels seen in the first and third quarters of last year, which had been hurt by higher costs tied to launching and ramping up new projects. During Q1, even though we largely held fourth quarter 2023 revenue levels, we managed to push margins higher by aligning overtime costs and subcontracted labor expenses more closely with the targets we've discussed on recent earnings calls. We saw solid sequential gains in both of these key metrics. In Q1 2024, subcontracted labor represented 31% of total hours worked, versus 41% in Q4 2023. Overtime made up 7% of total hours worked in Q1 2024, compared to 9% in Q4 2023, and down from our peak of 16% in the third quarter of 2022. Both metrics have kept trending lower in the second quarter so far, which is a good sign for Q2 margins. In Q1 2024, gross margin for the mobile health segment was 35.5%, versus 27.7% in Q1 2023, which had been affected by those project launch and ramp-up-related costs. In Q1 2024, we did see certain new projects ramping up, but a continuing margin gain on a number of our more established projects more than offset those effects; within our mobile health segment, our goal is a blended gross margin at or above 40%, so additional effort is still required, yet what we've achieved over the last six months has been quite heartening. Over in transportation, gross margins came in at 33.7% during Q1 of 2024, compared with 28.9% in the first quarter of 2023. Transportation gross margins keep gaining from greater scale, better utilization, and reduced fuel price pressure as well as a richer mix of trips, together with an ongoing move into leased-hour programs that carry higher margins. Q1 of 2024 represented the fourth quarter in a row in which transportation gross margins exceeded 30%. Our expectation is that transportation gross margins will remain approximately at today's level, notwithstanding certain wage pressures we anticipate in select geographies, since the market for EMTs is still tight. Switching to operating costs, SG&A came to 26.7% of total revenues in the first quarter of 2024, a far cry from the 34.2% recorded in the first quarter of 2023. Because revenues grew through the latter half of 2023 and into 2024, SG&A fell as a share of total revenues, which drove operating margin expansion; we likewise carried out a focused reduction in force in Q1, producing certain cost savings that should be realized as we enter Q2 and afterward. Moving on to the balance sheet, at March 31st, 2024, total cash and cash equivalents, restricted cash included, stood at $58.9 million, versus $72.2 million at the close of 2023. Our accounts receivable kept climbing, mirroring the revenue surge we saw across the latter half of 2023 and early 2024. Although we gathered substantial amounts in Q1, especially during late February, collections slowed through the last three weeks of the quarter, and then payments resumed flowing early in Q2. Regarding our project with New York City's Department of Housing Preservation and Development, HPD, as of today we have gathered close to 65% of the year-end 2023 accounts receivable tied to that particular project. What offsets those collections, however, are the sizable sums we have invoiced for 2024 so far, most of which remains uncollected. At the close of the quarter, we held roughly $210 million in accounts receivable from the various migrant programs, which amounts to approximately 75% of our total company accounts receivable. Although the wind-down of migrant-related programs will affect revenues, our balance sheet should gain considerably in 2024 as we collect this AR, resulting in better cash flow from operations. Beyond working capital uses in Q1, we drew on our cash balances to carry out our stock buyback program. Over the course of the quarter, roughly 1.3 million shares were bought back through open market transactions, totaling approximately $4.9 million in the aggregate. So far in Q2, under the provisions of our automated 10b5 to 1 trading plan, an extra 1.4 million shares have been repurchased for an additional $4.9 million. With about $10 million spent on buybacks thus far this year, a further $26 million is still available under that program. As Lee noted, we anticipate reduced migrant-related revenue for this year because of the expected accelerated wind-down of certain migrant projects; nonetheless, collecting the receivables referenced earlier will bring about an improvement in our working capital position. As older, larger invoices get collected and as our cash outflows decline in step with reduced migrant project expenditures, we would anticipate an increase in our cash balance. Accordingly, we now anticipate generating cash flow from operations of $70 million-$80 million in 2024, which exceeds the range we initially guided to at the time we reported our 2023 results at the end of February. At this point, I'd like to hand the call back to the operator for Q&A. Operator, please go ahead.

Ryan MacDonald

analyst
#4

Hi there. I appreciate you fielding my questions, and congratulations on a solid quarter. It's encouraging to see things getting cleaned up as we consider how the main business will perform going forward versus migrant contracts. Lee, perhaps to kick things off and get some clarity — as you look ahead toward 2025, you're anticipating the core operation will generate roughly $400 million in revenue along with $50 million of EBITDA. Do you anticipate any revenue tied to migrant contracts whatsoever? My impression was that it would come on top of that, but within your early outlook for 2025, do you still anticipate any migrant contracts whatsoever? Thank you.

Lee Bienstock

executive
#5

Thank you, Ryan. Thank you, Ryan. I appreciate that question. We truly wanted to separate out the base revenue, which is that $400 million figure you're referring to, and that is set to expand as we move through 2025. Whatever migrant-related revenues arise during 2025 would come on top of that. So it's definitely conceivable, based on how the crisis unfolds, based on how the deployment takes shape and what the city requires, it's conceivable that it might persist into 2025, though that would come on top of the $400 million from the base business.

Norman Rosenberg

executive
#6

Yes. Ryan, this is Norm, and I'll just build on what was said. We want to be sure we're clear on this point. The figures we're providing for 2025 aren't guidance—they aren't. They're really just a kind of scaling for everyone, so you can run your models on what we consider, loosely speaking, our base revenues. As 2025 gets nearer, we'll see more clearly what could be layered on top of that through migrant-related revenue, and that will make up our actual guidance for the period.

Ryan MacDonald

analyst
#7

Okay, that clears things up nicely. Now, when we look at the main business and how the 2025 figures break down — you mentioned $250 million from hospital systems, $100 million from municipal, and $50 million from payer and provider programs — could you help us understand the growth rates for each of those end markets as you look at this year and the next? There are plenty of strong initiatives you mentioned in there, but some color on that would be great. Thanks.

Lee Bienstock

executive
#8

Absolutely. The way I see it, where the pipeline sits for each of those businesses will really determine how those three segments grow. You brought up the hospital business. That's the medical transportation business we operate today, and from 2024 to 2025 we expect it to grow in the 15% range. Beyond that, we'll be adding additional mobile health programs alongside our health system partners, and that's another source of growth you'll see in 2025; it'll come both from hospital systems already working with us and from a pipeline of hospital systems that could become new partners — ones we're engaging with every single day. On the municipal side, I touched on this a bit, but our approach to growing that business is through what we refer to as population health, long-term sustainable RFPs and opportunities with municipalities. The traits we'll be seeking there are that these are long-term in nature, long-term programs rather than more crisis response. They bring in our core services — core medical services like vaccination deployment, behavioral healthcare services, and other infectious disease services within our core competencies — and they also bring in elements of our technology and our innovative delivery model; so going forward we'll assess RFPs against those three criteria. As before, we have our pipeline of RFPs, which we discussed on earlier calls, that we'll keep pursuing, and we'll seek out RFP opportunities that reflect those traits. Then when it comes to insurance, with our payers and provider partners and the monitoring business, that one, as we've said, is our smallest business right now. It's the fastest-growing piece of our portfolio, and its growth will come from broadening the payer relationships we currently have into new geographies, plus growing through new payer partnerships in our pipeline. I'd say it has the highest growth rate, though it's still coming off the smallest base.

Ryan MacDonald

analyst
#9

Yeah. There are so many strong opportunities, Lee. Once more, I truly appreciate all the extra detail you’ve provided on today’s call. Thank you.

Lee Bienstock

executive
#10

A: Thank you, Ryan.

Ryan MacDonald

analyst
#11

Yes. Thank you, and nice work on the quarter. Regarding the migrant topic, to be clear, we're grateful for the specifics about the anticipated revenue contribution. What I'd like to know is about NYC Health and Hospitals. My understanding is that this is a distinct contract covering migrant services. And are you indicating that you expect it to taper off or disappear? Any further information on that would be useful.

Norman Rosenberg

executive
#12

Of course, Richard. Allow me to take you through it. To begin broadly, basically, we are reducing the projection for revenues tied to migrants by roughly $100 million, more or less, if you set our prior guidance beside the present guidance. Nearly all of that amount is connected to HPD. That comes from a pair of separate reasons. First, there's the shift away from certain locations in New York City, the ones referred to as downstate locations, and next the now-expected conclusion of the upstate locations too, which, admittedly, is a forecast. No schedule exists for that as of yet, though we are anticipating it. Regarding the H&H portion of the business, if I compare what I'd term the earlier projection against the present projection, it's essentially unchanged. The migrant work linked to H&H clearly will involve certain locations shutting down, while other locations last somewhat longer. Yet accounting for the additions and subtractions, basically that figure barely shifts; and I can provide that breakdown for you. Specifically, we estimate H&H at approximately $180 million for the entire year, whereas the HPD-related items come to roughly $150 million, which is lower than an earlier expectation of around $250 million; therefore the whole difference is truly accounted for by the assorted components of the HPD programs and contracts.

Richard Close

analyst
#13

All right, but does H&H have a conclusion date, or not? My apologies — that simply escaped me.

Lee Bienstock

executive
#14

Right, at this point the H&H engagement doesn't have a set completion date. Our support for Health and Hospitals will carry on. They rank among the partners we've worked with longest. Over the years, we've partnered with them across a wide variety of healthcare rollouts and requirements. So no finishing date exists for that. Naturally, as we learn more about how those initiatives take shape, we'll share updates. As things stand, though, no conclusion date is attached to it. Every one of those H&H projects was put out for bid. At first we delivered services through an emergency procurement, after which those services were sent to bid, and we did launch new contracts in that process. Those should last about a year, counting from now or from the last few months. Still, based on what's needed, we'll keep delivering those services, though nothing is scheduled to wrap up at present. As we find out more and more on the way into 2025, naturally, we'll bring you updates.

Richard Close

analyst
#15

All right, that's useful. Then perhaps I could add something after Ryan's question regarding 2025, just so we're clear on it, Norm — the $400 million is more or less a goal. And from what I hear, that's work already signed, which you're in the process of carrying out right now, plus a bit of anticipated expansion or scaling up of particular agreements, such as the managed care contracts. Is that right, or is there, pardon me, a certain amount of hunting for new business inside that $400 million?

Norman Rosenberg

executive
#16

Sure. So when we're looking at revenue that lands somewhere between 6 and 18 months from now, there's bound to be a portion of that which is still upside. A great deal of it ties back to the objectives that have already been shared internally. But when you really break it down, as we mentioned, $225 million of that figure would come from transport. Compare that with approximately $195 million or $200 million for the current year, and what you get is growth — double-digit growth, though on the lower end of double digits. As for the payer programs and items in that bucket, we're likely heading toward $25 million or $30 million this year, so essentially that nearly doubles to around $50 million. Several factors drive that. It comes down to targets and goals regarding how many patients we anticipate having and how many agreements we expect to sign. Then with the hospital system, since we view it as not a vertical but rather a segment, we're assuming — as Lee pointed out — that perhaps 10% of that $250 million figure from hospitals is mobile health rather than transport. Those assumptions rest on certain deals, some of which are in the signing stage, while others sit a bit further along the funnel. Much of it is already accounted for, but yes, there's certainly some upside built in. Still, each dollar of that upside revenue is tied to something within the funnel.

Lee Bienstock

executive
#17

Right, Richard — the one point I would make is that this really comes from putting together the underlying business, the agreements already in place, and every partner we currently have as of now, and on top of that, it reflects what's in the pipeline for both this year and the following year, covering all the different partners and every stage of that pipeline across this year and next year.

Norman Rosenberg

executive
#18

Right. Yet there's something significant that everybody should really take note of, and we would definitely be discussing it internally here as well. The individuals who will be going out there obtaining that revenue and growing that pipeline are the very same individuals who, across the past 2 years, or most of the past 2 years, have been concentrating on a portion of this migrant revenue. So although there was unquestionably an opportunity cost during the last couple of years, there is what you might call "an opportunity benefit" ahead of us, as we concentrate on expanding that base; therefore we aren't rejecting migrant work, but when it comes to business development efforts, when it comes to other operational efforts, the emphasis will unmistakably be placed on the base.

Richard Close

analyst
#19

Okay. Thank you very much.

Lee Bienstock

executive
#20

Of course.

Ryan MacDonald

analyst
#21

Hi. Could you discuss the payer-facing side of things? Perhaps share what kind of demand you're observing when it comes to closing care gaps. Who do you compete against there? It sounds like your offering is quite distinctive and would appeal to health plans. Then maybe you could also touch on the virtual primary care side of things. It appears plans might gain from that too; and my sense is that all of this likely contributes to better star ratings, which clearly matter a great deal to health plans. So any additional detail would be quite useful. Thank you.

Lee Bienstock

executive
#22

Sure. Thanks, David. Good to hear from you. I appreciate the question. So yes, exactly as you framed it, we are certainly witnessing demand around care gap closure. The main force behind this is health plans putting serious resources into lifting their quality scores, boosting their HEDIS star measures, and genuinely ensuring they affect their members and their patients, their member base, their health outcomes. There's a huge opportunity we see to work with these health plans, a lot of which have millions of members, so we can reach those people who have care gaps and face accessibility problems. I'd say our competitors are mainly the physical, brick-and-mortar clinics that health plans have historically attempted to steer or push patients toward so those care gaps could get closed. Clearly, our approach is quite different. Rather than phoning a patient and telling them, "You need to visit our clinic for a bone density scan," or, "You need to come to the office for a diabetic eye exam," what we do is call the patient and tell them, "Hey, we're nearby; we know you have a care gap that needs closing. You need a colon cancer screening. We're nearby. We'll visit your home. Does tomorrow work? Does next week work?" And we believe we offer a genuinely differentiated patient experience that I'd say is proving effective and highly valuable, and patients are enthusiastic about it. So that's essentially where the demand comes from for us. That's roughly the competitive landscape. Naturally, other mobile providers exist, but our service delivery model is truly one-of-a-kind because it merges our tech platform. We can efficiently optimize the field clinicians we employ; we give them the technology they require, and then we connect them with. We pair them with an advanced practice provider who is guiding the clinical encounter from a distance. So, a truly distinctive model. And clearly, delivering care to patients and meeting them where they are makes it far more probable that health outcomes will improve; when it comes to virtual care, when it comes to the primary care practice business, the PCP business you brought up, we feel strongly there too that our model is differentiated. So, picture this: as we're out there bridging care gaps, getting patients involved right in their own homes, and building that connection, we've got a chance to step in as their main doctor. We can also sort of take the lead on steering their treatment, assist in organizing it, and make a real, deeper difference in their health. That's why we see potential in this area. So when we connect with patients and fill those care gaps, it opens the door for us to serve as their primary care provider, since maybe they can't find one, or it's been more than a year since they last visited one, or they struggle to reach their PCP, or scheduling with the PCP is tough for them. Our approach is distinct because we basically deliver the PCP right to them. So as we work on bridging care gaps, that creates a kind of organic pathway for us to also step in as their PCP; and while we're assisting with care coordination and filling those gaps, you can see how we'd succeed in boosting star ratings and HEDIS quality score metrics. Clearly, that's a win for the patient. It's a win for the plans and in the end contributes to reducing expenses across the whole system. We'll be part of that; we're thrilled about that pathway; we believe the value proposition is definitely present. The patient experience is definitely present. It's a truly unique option compared to what exists now. We're eager to grow it and put resources into it.

Ryan MacDonald

analyst
#23

All right. That's really useful. And then I just want to ask one quick follow-up about the primary care business. The virtual primary care companies I know about grow extremely quickly. PlushCare, which is part of Accolade, I believe is their fastest-growing segment. LifeMD is growing very fast too. What would the revenue model look like? Might it be something like $100 per month paid directly by consumers? And then, I mean, assuming 10,000 patients, I think that would come to about $12 million in revenue per year. Or would you maybe take on risk and get a percentage of premium? Or is that still being worked out, and you'll just kind of watch where the market's need is?

Lee Bienstock

executive
#24

Yeah. So I believe it's key to understand that our real point of difference, as we see it, is virtual care when that works well, plus the option to see someone in person when that's required. And a lot of the time, it simply is required. And I think many healthcare organizations are discovering this as they operate telehealth only. They truly do need that clinical care delivered in the home. So that, as we see it, is genuinely our point of difference — not only on the virtual side, but we're also bringing the in-person piece into the mix. And sometimes we'll deliver care virtually, but when it's required, we can do it in person. Our approach to making money on this, I think, is really just what you laid out. At first, I think we'll have a per member or per patient per month fee, basically, that is billed either to the health plan or to a commercial payer. And then down the road, once we've got the data, once we're at ease with it, certain contracts we're signing include the option for us to move into risk sharing, at the start upside only, and later on full risk once we're at ease, once we believe we're truly making a difference in patient outcomes and bringing down the total cost of care. But we're setting things up so that it happens in stages, rather than everything at once.

David Larsen

analyst
#25

All right, thank you so much. I'll rejoin the line.

Lee Bienstock

executive
#26

Thank you, David. I appreciate that.

Ryan MacDonald

analyst
#27

Hello. Kieran Ryan is here in place of Pito. I appreciate you taking my question. I was just curious whether there's anything you could share that might give us a better grasp of what the margin looks like on your base revenues at present or during 2024, particularly as we consider how that bridges toward the 12.5% figure for 2025, based on the $400 million in revs and $50 million in EBITDA. Thanks.

Norman Rosenberg

executive
#28

Absolutely. This is Norm. Regarding gross margin, the transport business is one we report separately without much difficulty. It comes in at roughly 33 and change. That's the level we're operating at. Clearly, the EBITDA margin there varies depending on the approach you take to allocating overhead. Turning to mobile health, let's begin with gross margin. It's likely around 35% and change. In fact, if you separate out migrant, that figure could be somewhat greater. Certain migrant revenues, particularly the programs that will be among the earliest to launch, tend to carry lower margins. So my sense is the mobile health base gross margin sits in the high 30s. How we arrive there, though, involves a blended gross margin that we describe as, say, 35 points, followed by SG&A representing roughly 23 points as a share of revenue. From there you reach EBITDA of 12 or 22.5 points. What complicates matters is having three separate SG&A categories. We have Mobile Health SG&A, which is fairly variable. So that ought to decline when the revenues for the migrant portion come out. Transport revenues are likewise — well, transport SG&A is typically tied on a variable basis. What will be challenging for us is the effort that has already begun, that is already in progress, which is ensuring we right-size our corporate expenses. So how do we handle our corporate expenses in a manner that lets us scale it for a company generating, say, $400 million or so in revenue, or somewhat above that, rather than $600 million or $700 million? That said, this is the effort that must be completed as we scale and right-size the remainder of the business; but that's roughly how we arrive there, 35% gross margin on a blended basis, close to where we stand today, and then roughly 23 points on the SG&A side, which brings you to an adjusted EBITDA margin of approximately 12%-12.5%. So the margin characteristics appear — they appear quite comparable, in fact, to what we have here in Q1.

Ryan MacDonald

analyst
#29

Right. That suggests your view that gross margins per quarter will remain fairly steady this year versus 4Q23 probably hasn't shifted much?

Norman Rosenberg

executive
#30

Yeah. I'd say we're quite pleased, since we're seeing gross margin keep getting better both sequentially and, naturally, versus a year ago, and beyond that, I'd note that figure is quite tidy and straightforward. You didn't see many expense adjustments or anything of that sort. There was no accrual reversal or the usual accounting items that can appear in a quarter and push your margins either up or down. Almost nothing was non-recurring in nature; what we saw this quarter was basically a pure, clean margin; of course, there will always be elements that apply some pressure to margins at times. Yet likewise, there are elements that push it the opposite way. So we believe we should remain around this general area for a good while. As I mentioned on the call, items such as overtime keep moving favorably, even better than in Q1. Items such as subcontracted labor as a percentage of hours or cost, depending on how you view it, are likewise moving favorably. So when we examine those KPI, the signal is flashing green. So that's good.

Ryan MacDonald

analyst
#31

Thanks.

Sarah James

analyst
#32

Thank you. To clear up what was asked before, it seems that once HPD revenue is removed, no shift in the expense mix should be anticipated across the cost of revenue and G&A categories, since your mix for that operation is close enough to what you have in the core, meaning those ratios ought to remain fairly steady. Is that accurate?

Norman Rosenberg

executive
#33

Sarah, looking at it in the aggregate, you've got that right. In practice, regarding when things occur, it turns out that the initial projects, or the initial sites, slated for transition are the very ones carrying lower gross margins. So technically, you would notice a slight uptick. Then again, we didn't pick it that way, it wasn't as if we hand-selected those sites or anything of the sort. That's simply how it fell out. And in particular regions, particular sites are inclined to be somewhat less profitable. Still, in the aggregate, once you consider the projects on a blended basis, their margin profile isn't dramatically distinct from that of the remaining business.

Sarah James

analyst
#34

All right, that's helpful. Is there any insight you could give us regarding seasonality for this year, particularly as that contract tapers off, while you're comparing it against expansion in a few of your other segments? What's the right way to think about how much the first half contributes relative to the second half?

Norman Rosenberg

executive
#35

What I'd say is, there will be some seasonality involved — or I guess more accurately, a fluctuation rather than true seasonality — but a fluctuation from one quarter to the next. Basically, the way I'd frame it is that total revenue, blended revenue, is going to move downward, because even though core revenue will rise sequentially — and I feel fairly confident about that — and if you compare our Q1 results against the full-year projections we've provided for the core business, those numbers should climb as each quarter passes. That assumption rests on specific projects we're preparing to roll out, on both the transport side and the non-migrant mobile health side. Even so, that won't be enough to offset — or rather, it will be more than offset by — the drop in HPD revenue. So what we expect is HPD revenue falling quite substantially in Q2, and then potentially getting cut in half once more in Q3. Then by Q4, our guidance and projections reflect almost no meaningful contribution at all from that contract. That gap is large enough that it will surpass the gains in core revenue. So when I look at our total revenue on a sequential basis, the current picture is this: Q1 will turn out to be the peak for our quarterly revenues in 2024. From there it declines in Q2, falls even more in Q3, and likely continues to slide in Q4, all depending on when some of that other revenue starts to come in.

Sarah James

analyst
#36

Excellent. That brings us to our final question. Is there anything you can share regarding how payables, the accounts payable balance, grew during the quarter?

Norman Rosenberg

executive
#37

You're asking about accounts payable?

Sarah James

analyst
#38

Mm-hmm.

Norman Rosenberg

executive
#39

Sure. One interesting item we track is this: we noted that we brought in a substantial amount of cash across the quarter. Even so, as you've clearly observed, the strain on working capital has persisted. Take a look at the balance sheet, which appeared in both the release and our 10-Q — that was filed today too, immediately following the close — and you'll see that not only did AR rise, but specific payable levels declined, meaning prepaid expenses and items along those lines. So, to give everyone the full picture, my estimate is that from the various migrant and related programs, we brought in roughly $120 million across the quarter. At the same time, though, there's obviously a great deal of large payroll running against that. After that, we disbursed payables amounting to nearly $80 million-$90 million, close to $90 million, on those projects. Something we've been talking about here internally: we aren't able to simply align paying those payables with the moment the money arrives. Payment has to go out before we can get paid; frequently, we need receipts proving we've paid the underlying providers. So we can stretch it somewhat, yet turning that working capital cycle around is truly not something we have the luxury of doing. On these migrant revenues, our working capital cycle sits in negative territory, and that will remain true always. Another point: many of these vendors matter greatly to us, and they are highly important vendors; they're small businesses, minority-owned businesses in certain instances, privately held businesses. Waiting 4, 5, 6 months to be paid isn't something they can afford, even if we decided to go that route. Thus, when you're handling revenues of this type, substantial working capital pressure will always exist. That's what surfaced again during the first quarter.

Sarah James

analyst
#40

That's really useful. Thanks.

Aditya Dagaonkar

analyst
#41

Hello. Aditya here, calling in for Mike Latimore. Could you share a bit of detail on whether the chatter regarding the migrant care is having an impact on your other deals in NYC or the state?

Lee Bienstock

executive
#42

Of course. Glad to take that one. I believe I caught it. Would you mind repeating the final portion of your question?

Aditya Dagaonkar

analyst
#43

Is the chatter surrounding your migrant care business having an impact on other deals you're pursuing in New York City or across the state?

Lee Bienstock

executive
#44

Yes. That chatter is definitely something we keep an eye on. All of our existing partners, plus everyone in our pipeline, are in close contact with us. Any time chatter pops up or something inaccurate appears in print, we act quickly. We reach out to every current partner and every prospective partner, and we set the record straight. Naturally, the partners already working alongside us understand how good our work is and truly appreciate the partnership. That allows us to effectively put that chatter to rest. Honestly, that's among the things we're eager to put behind us. Sadly, a great deal of the migrant-related revenues got politicized, and because of that, some chatter emerged — chatter in the market among our investors, and possibly chatter in the market among customers — which I believe we've managed extremely well. So it's something we're watching closely. There's been a single partner who asked to pause until the chatter dies down. That partner is in close contact with us. Everyone else we work with, though, remains closely engaged with us. We keep tackling whatever chatter arises, and it hasn't turned into a problem. As for our prospective pipeline, we keep everyone updated along the way. We genuinely believe our value proposition for prospective partners, along with how good our work is for every partner we have today, truly speaks for itself. One terrific thing we get to do is connect any prospective partners directly with our current customers as references. We've pulled that off very, very successfully. Our current customers serve as excellent references for us — they attest to how good our work is and what the experience of working with us and partnering with us is like. We've also leaned on that to assist in the sales process.

Aditya Dagaonkar

analyst
#45

Understood. Would you be able to share additional detail regarding what proportion of operating cash flow relative to EBITDA we should anticipate for this fiscal year?

Norman Rosenberg

executive
#46

Yes. Certainly. As you've heard, or I hope you heard, despite the fact that we lowered our EBITDA assumption somewhat, we are in fact raising the cash flow from operations figure. To clarify, by cash flow from operations, I mean that GAAP line item appearing in your statement of cash flows. And what we're indicating is that we now anticipate that figure will land somewhere between $70 million-$80 million, which is in fact somewhat above the EBITDA we've projected. Ordinarily, we ought to be operating at a — since we are taxpayers, that plays a role in this. We ought to be operating at a — I'm not certain. If everything else stays constant, roughly 80% or so of adjusted EBITDA converts into operating cash flow. What we've incorporated is that should we experience a reduction in this migrant revenue base, then clearly, as we work through our model, that will lead to receivables being collected more quickly than the payments we make throughout the year. So over the coming 2, 3 months, we'll be gathering on older invoices. At the same time, though, we're disbursing less money, which is something like a reversal of certain working capital problems we've encountered across the last 3 to 4 quarters. Take Q1 as an illustration: if you examine our statement of cash flows, I believe the figure was negative $10 million and change during the first quarter; roughly $10 million or so was used in operations; on a full-year basis, that figure ought to fall somewhere within the $70 million-$80 million range, set against Adjusted EBITDA in the $65 million-$75 million range. Thus, for the full year, we'd anticipate it coming in somewhat above 100%, recognizing that much of this stems from the positive working capital changes we'll see in Q2, Q3, and Q4.

Aditya Dagaonkar

analyst
#47

Got it.

Lee Bienstock

executive
#48

Thank you.

David Grossman

analyst
#49

Hello, and thanks. These are just a couple of very fast questions. First, since I'm traveling, I don't have a monitor in front of me. But did you provide the core growth rate you anticipate for 2024? In other words, once you strip out migrant work for both 2024 and 2023, what does that core growth rate come to? What growth rate are you assuming as the basis for the guidance?

Norman Rosenberg

executive
#50

My apologies. Are you referring to revenue excluding migrants for 2024?

David Grossman

analyst
#51

Okay, got it.

Norman Rosenberg

executive
#52

Yes. For 2024, we're figuring non-migrant revenue at approximately $300 million, and that is.

David Grossman

analyst
#53

Okay, so from a growth standpoint, how does that compare against the prior year?

Norman Rosenberg

executive
#54

If I focus only on those particular line items, compared with the prior year, it's essentially unchanged. What explains that is that transport should rise from roughly the low 180s up to the mid- to high 190s — that works out to something like 10% on the transport side — while on the non-migrant mobile health side, we had a few sizable municipal projects that I would describe as COVID-adjacent. They weren't testing projects, but they were projects tied to vaccination that we carried out during the first three and a half months of 2023. That amounted to roughly $25 million, plus perhaps another $5 million or $10 million from other projects that lapsed in the early part of 2023. So looking at all of that, the figure declined slightly. Excluding those items, it rose a little. Consequently, on a blended basis, we generated approximately $300 million in what you'd regard as those core revenues during the prior year, and we anticipate generating $300 million in the current year.

David Grossman

analyst
#55

Understood. Appreciate it. And regarding those margins by segment, did you give them? Are the segment EBITDA margins sitting in the queue, by any chance, for transport?

Norman Rosenberg

executive
#56

In the same manner we've separated it out, since we do have the corporate. And I'm aware you all distribute the corporate portion. But indeed, all of that is included there.

David Grossman

analyst
#57

Great. Okay. That's all I have. Thanks once more. Yeah.

Norman Rosenberg

executive
#58

Yep. Yep.

Lee Bienstock

executive
#59

Appreciate it. I want to thank everyone for being here with us today. We can't wait to talk with all of you again before long about everything we've been achieving. Take care.

Operator

operator
#60

Much appreciated, sir. Everyone, that brings today's call to a close. We're grateful you took part. At this point, please hang up your lines.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete DocGo Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to DocGo Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in DocGo Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.